位置:首页 > 产品库 > Lck Inhibitor
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Lck Inhibitor
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Lck Inhibitor图片
CAS NO:847950-09-8

Lck Inhibitor 是一种有效的口服活性淋巴细胞特异性激酶 (Lck) 抑制剂,对 Lck,Lyn,Src 和 Syk 激酶的IC50分别为 7、2.1、4.2 和 200 nM。与 MAPK,CDK 和 RSK 家族代表相比,Lck Inhibitor 对 Lck 的选择性高出 1000 倍以上。Lck Inhibitor 抑制 T 细胞增殖和关节炎模型。
生物活性

Lck Inhibitor is a potent, orally activeLck (lymphocyte specific kinase)inhibitor withIC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn,SrcandSykkinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK,CDKand RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis[1].

体外研究
(In Vitro)

Lck Inhibitor (compound 25) exhibits good potency in the T-cell receptor-induced IL-2 secretion assay (IL-2, IC50=0.46 μM) and also inhibits subsequent T-cell proliferation (T-cell prolif, IC50=0.53 μM) in the same human T-cells. Lck Inhibitor also inhibits a human mixed lymphocyte reaction (huMLR) with a 10-fold increase in potency as compared to the other invitro cell assays utilizing purified human cells. Lck Inhibitor also displays inhibition of a mechanism-based biochemical cell assay probing Lck-dependent TCR-chain phosphorylation (TCR-chain). Lck Inhibitor shows a 10-fold reduction in potency when IL-2 is induced in a receptor-independent fashion by stimulating with phorbo lester and calcium ionophore (PMA/iono). Lck Inhibitor exhibits a similar level of potency when tested in a general proliferation assay using the human T-cell line, Jurkat (JKT)[1].

体内研究
(In Vivo)

Lck Inhibitor (0-60 mg/kg; p.o.; once daily; from day 9 today 17) shows a dose-dependent inhibition of arthritis[1].
Lck Inhibitor (p.o.; 5 mg/kg) treatment shows the Cmax, AUC0-∞, tmaxand F% are 82 ng/mL, 862 ng h/mL, and 17%, respectively[1].

Animal Model:Male Lewis rat (adjuvant-inducedarthritis model)[1]
Dosage:0, 30, and 60 mg/kg
Administration:P.o.; once daily; from day 9 today 17
Result:Showed a dose-dependent inhibition of arthritis, with an ED50estimated at 24 mg/kg.
Animal Model:Sprague-Dawley Rats[1]
Dosage:P.o. (Pharmacokinetic Analysis)
Administration:5 mg/kg
Result:The Cmax, AUC0-∞, tmaxand F% were 82 ng/mL, 862 ng h/mL, and 17%, respectively.
分子量

530.62

性状

Solid

Formula

C31H30N8O

CAS 号

847950-09-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder-20°C3 years
4°C2 years
In solvent-80°C6 months
-20°C1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL(188.46 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.8846 mL9.4229 mL18.8459 mL
5 mM0.3769 mL1.8846 mL3.7692 mL
10 mM0.1885 mL0.9423 mL1.8846 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.71 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (4.71 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024